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Abstract
Some trace metals may increase risk of amyotrophic lateral sclerosis (ALS), whereas others may 
be beneficial. Our goal was to examine associations of ALS with blood levels of selenium (Se), 
zinc (Zn), copper (Cu), and manganese (Mn). We conducted a case-control study of 163 
neurologist confirmed patients from the National Registry of Veterans with ALS and 229 
frequency-matched veteran controls. We measured metal levels in blood using inductively coupled 
plasma mass spectrometry and estimated odds ratios (ORs) and 95% confidence intervals (CIs) for 
associations between ALS and a doubling of metal levels using unconditional logistic regression, 
adjusting for age, gender, and race/ethnicity. ALS was inversely associated with both Se (OR=0.4, 
95% CI: 0.2–0.8) and Zn (OR=0.4, 95% CI: 0.2–0.8). Inverse associations with Se were stronger 
in patients with bulbar compared to spinal onset, worse function, longer diagnostic delay, and 
longer collection delay; inverse associations with Zn were stronger for those with worse function 
and longer collection delay. In contrast, ALS was positively associated with Cu (OR=3.4, 95% CI: 
1.5–7.9). For Mn, no linear trend was evident (OR=0.9, 95% CI: 0.6–1.3, Ptrend=0.51). 
Associations of Se, Zn, Cu, and Mn with ALS were independent of one another. Adjustment for 
lead levels attenuated the positive association of ALS with Cu but did not change associations with 
Se, Zn, or Mn. In conclusion, Se and Zn were inversely associated with ALS, particularly among 
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those with worse function, suggesting that supplementation with these metals may benefit such 
patients, while Cu was positively associated with ALS. Deficiencies of Se and Zn and excess Cu 
may have a role in ALS etiology.
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1. Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease affecting 
motor neurons in the brain and spinal cord (Wijesekera and Leigh, 2009). Most patients are 
in their fifties and sixties, and ALS is more common in men than women (Wijesekera and 
Leigh, 2009). ALS has a complex etiology: about 10% of patients have a family history of 
ALS, and their disease may have a genetic origin; the remaining 90% are likely due to a 
combination of genetic and environmental factors, with the latter playing an important role 
(Al-Chalabi and Hardiman, 2013).
Metal exposure is a potentially relevant environmental factor, although previous studies have 
produced inconsistent results, perhaps partly attributable to limited exposure assessment 
(Sutedja et al., 2009). Few studies have evaluated metal exposure using levels measured in 
blood or other tissues. Lead (Pb), the metal most often studied using measured levels, is 
generally positively associated with ALS risk (Fang et al., 2010; Kamel et al., 2005). Studies 
of other metals, including selenium (Se), zinc (Zn), copper (Cu), and manganese (Mn), have 
primarily evaluated the presumed toxic effects of high exposures (Bergomi et al., 2002; 
Garzillo et al., 2014; Kapaki et al., 1997; Nagata et al., 1985; Pamphlett et al., 2001; Roos et 
al., 2013; see Supplemental Table 1). Metal deficiencies could also plausibly increase ALS 
risk because metals are essential trace elements and play a role in mitigating oxidative stress 
as well as other critical cell processes (Jellinger, 2013). Previous studies have yielded 
inconsistent results, possibly because of small sample sizes, choice of comparison groups, or 
the different types of samples used for measurement (Supplemental Table 1). No previous 
study has evaluated modification of the ALS-metal associations by clinical features, such as 
site of onset.
For the present analysis, we used data from the Veterans with ALS and Lead Exposure 
(VALE) study, a case-control study of US military veterans (Fang et al., 2010). We focused 
on four trace metals, Se, Zn, Cu, and Mn: Se because it has been reported to increase ALS 
risk (Vinceti et al., 2010); Zn and Cu because they are co-factors for superoxide dismutase 
(SOD1), an enzyme implicated in familial ALS (Trumbull and Beckman, 2009); and Mn 
because it has been implicated in neurodegenerative disease (Jellinger, 2013). In addition, 
Se, Zn, and Cu all affect oxidative stress (Jellinger, 2013; Navarro-Alarcon and Cabrera-
Vique, 2008), a mechanism potentially involved in ALS pathogenesis (Wijesekera and 
Leigh, 2009). We report associations of ALS with these metals, variation of these 
associations by clinical features and effects of Pb on the relationships between ALS and 
each of the four metals.
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2. Materials and Methods
2.1 Study Population
VALE patients came from the US Department of Veterans Affairs (VA) National Registry of 
Veterans with ALS (VA Registry) (Allen et al., 2008). Veterans or their caretakers who 
passed a telephone screening questionnaire were asked to provide medical records, and 
approximately half donated blood samples for a DNA bank (DiMartino et al., 2007). 
Neurologists specializing in motor neuron disease (MND) used information from the 
medical records to assign a diagnosis using an algorithm based on the revised El Escorial 
Criteria (Brooks et al., 2000). The VALE study included a subset of VA Registry patients 
who donated blood samples between January and September 2007. Our main analyses 
focused on 163 patients with clinically definite, probable, or possible ALS. We also 
considered a broader group of MND patients consisting of these ALS patients plus 30 
persons diagnosed with progressive muscular atrophy; patients with primary lateral sclerosis 
were excluded from all analyses.
VALE controls came from the Genes and Environmental Exposures in Veterans with ALS 
(GENEVA) study (Schmidt et al., 2008). GENEVA identified controls from an age-stratified 
random sample of 10,000 US veterans obtained from the Veterans Benefit Administration in 
June 2005. Veterans free of ALS and other neurological disorders were frequency matched 
to GENEVA patients on age within five years (age at diagnosis for patients and age at 
interview for controls), and use of the VA health care system before diagnosis/interview (as 
a proxy for socioeconomic status). For VALE, controls already enrolled in GENEVA were 
contacted between May 2007 and May 2008 and invited to donate a blood sample during a 
home visit. Of 359 controls contacted, 252 consented to participate, and 229 donated a blood 
sample.
Institutional Review Boards of the National Institute of Environmental Health Science, the 
Durham VA Medical Center, Duke University, and Copernicus Group approved VALE. All 
study participants provided written informed consent.
2.2 Blood Collection and Metal Measurements
For VALE patients, blood collection procedures were the same as those for other VA 
Registry patients (Allen et al., 2008) except for the addition of a whole blood sample in a 6-
mL BD Vacutainer blue-top Trace Element metal-free tube (Becton, Dickinson and 
Company, Franklin Lakes, New Jersey) for metal measurement; this tube was collected first. 
Like patients, VALE controls provided two samples collected during home visits: a 6-mL 
whole blood sample in a metal-free tube, collected first, and a 9-mL plasma sample. 
Samples for cases and controls were processed similarly. For both, blood samples were 
chilled and shipped cold. Upon arrival at the lab, plasma samples were separated and whole 
blood and plasma samples were frozen within 48 hours of blood draw and stored at −80°C 
until assay.
The present analysis focused on Se, Zn, Cu, and Mn; Pb was considered as a covariate 
because it has commonly been associated with ALS. We determined metal concentrations in 
1.0 ml whole blood by inductively coupled plasma mass spectrometry (ICPMS) as 
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previously described (Fang et al., 2010). All batches included both cases and controls. 
Sample contamination was minimized by using a class 100 plastic hood and trace metal-free 
reagents (oxidants, 18-MΩ-quality deionized water, and ultrex-grade acids). Detection limits 
were 0.113 μg/dl for Se, 6.24 μg/dl for Zn, 0.234 μg/dl for Cu, and 0.124 μg/dl for Mn. 
Assay precision was good, with percent relative standard deviation ~2% for all four metals. 
To additionally monitor precision, 5% of cases and controls underwent preparation and 
analysis twice; agreement was ≥95% for all duplicates except for Zn, where agreement was 
≥80%. Because the assay was optimized for Pb measurement, no external standards for other 
metals were evaluated. However,values for reagent blanks, included in all batches, were 
below the detection limit for all four metals. Accuracy was evaluated as percent relative 
error using spiked blood samples; values were 68% for Se, 5% for Zn, −17% for Cu, and 
−8% for Zn. The high recovery for Se, contributing to the increased % relative error, is due 
to spectral interference that can impart a consistent positive bias to biological samples unless 
a tuning gas is used. This gas can interfere with sensitivity for detection of Pb and hence was 
not used. Historical data for Se from the laboratory indicated % relative error of −18% for 
spiked reagent blanks and 10% for spiked blood samples.
2.3 Covariates
Information on covariates including age, gender, race (White, other), ethnicity (Hispanic, 
non-Hispanic), and smoking (ever, never) was collected by interview for both patients and 
controls. We combined race and ethnicity to create a single race/ethnicity variable (non-
Hispanic White, other).
For patients, we obtained clinical information such as site of onset (spinal, bulbar) and dates 
of symptom onset and first diagnosis from medical records. We used the latter two variables 
to create the variable diagnostic delay, defined as the time from symptom onset to diagnosis 
and categorized as ≤ 1 vs. > 1 year. We defined collection delay as the time from diagnosis 
to blood collection and dichotomized it at the median (≤ 13 vs. > 13 months).
Patients enrolled in the VA Registry completed follow-up interviews at approximately six 
month intervals. During each interview, participants’ functional status was monitored using 
the revised ALS Functional Rating Scale (ALSFRS-R) (Gordon et al., 2004). The ALSFRS-
R score has a possible range 0–48 with a lower score representing worse function. For the 
present analysis, we used the score determined closest to the time of blood draw and 
dichotomized at the median (≤ 29 vs. > 29).
2.4 Statistical Analysis
We calculated Spearman correlation coefficients to evaluate associations between each pair 
of metals among controls, ALS patients, and MND patients. We used unconditional logistic 
regression models to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for 
associations between blood metals and ALS or MND. We assessed model fit using the 
Akaike information criterion (AIC). We used both categorical and continuous versions of the 
metal variables. For the former, we created categories using quintiles of metal levels among 
the controls as cut points, taking the group with the lowest levels as the referent. For 
continuous variables, we log2-transformed the metal levels to ensure linearity in model fit 
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and reported Ptrend from models using these variables. We always adjusted for age 
(continuous), gender, and race/ethnicity and sometimes additionally adjusted for smoking, 
Pb, or the other metals in addition to the metal of interest, as potential confounders.
To evaluate whether associations between metals and ALS or MND varied across sub-
groups of patients, we used multinomial logistic regression models with three outcome 
categories: controls and two disease sub-groups defined by site of onset, dichotomized 
ALSFRS-R score, dichotomized diagnostic delay, or dichotomized collection delay. We 
adjusted multinomial logistic regression models only for age (continuous) and race/ethnicity 
due to the small number of female cases (n = 3) in the study.
We used SAS 9.3 (SAS Institute, Cary, NC) for all statistical analyses.
3. Results
Characteristics of the study participants are presented in Table 1. The average reference age 
(diagnosis for patients, interview for controls) among all participants was ~63 years. Most 
participants were men, non-Hispanic Whites, and ever smokers. The most common 
diagnosis among patients was clinically probable ALS, and most patients had spinal onset. 
Whole blood Zn, Cu, and Mn levels among VALE controls were similar to their respective 
levels in other populations, whereas Se levels among VALE controls were higher than in 
European populations, as were Se levels in the US population as a whole reported in 
NHANES (Alimonti et al., 2005; Bocca et al., 2011; Heitland and Koster, 2006; Jain et al, 
2014; Rosborg et al., 2007; see Supplemental Table 2).
In general, pairwise correlations among the four metals and lead were weak – the maximum 
absolute Spearman correlation coefficient was 0.23 among controls, 0.30 among ALS 
patients, and 0.35 among MND patients – although some were statistically significant. 
Statistically significant correlations included a positive correlation between Zn and Se 
among controls but not among ALS or MND patients; a positive correlation of Cu and Pb 
among controls and ALS patients but not MND patients; and a positive correlation of Zn 
with Mn and a negative correlation between Zn and Cu among all three groups 
(Supplemental Table 3).
As judged using the AIC, model fit was essentially the same for the categorical and 
continuous variables for Se, slightly better for the continuous variables for Zn and Cu, and 
notably better for the categorical variable for Mn (Table 2). After adjustment for age, gender, 
and race/ethnicity, both Se and Zn were inversely associated with ALS, whereas Cu was 
positively associated with ALS, regardless of whether categorical or continuous variables 
were used (Table 2). The relationship of Mn with ALS was non-linear (Ptrend=0.51) with an 
inverted U shape, with the strongest association observed in comparing the middle to the 
lowest 20% (OR=2.3, 95% CI: 1.2–4.3). For all metals, results for MND were qualitatively 
the same as those for ALS (Table 2).
Additional adjustment for smoking did not change associations of ALS with any of the 
metals (Table 3). Adjusting for Pb did not change associations of ALS with Se, Zn, or Mn, 
but it attenuated the positive association of ALS with Cu (Table 3). Including all four metals 
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of interest as well as Pb in the models gave essentially the same results as adjusting for Pb 
alone: associations of ALS with Zn, Se, and Mn were similar to those from models with 
only the metal of interest, although less precise, and the positive association with Cu was 
attenuated (Table 3).
Comparing ALS patients with different clinical features (spinal vs. bulbar site of onset, 
lower vs. higher ALSFRS-R score, shorter vs. longer diagnostic delay, shorter vs. longer 
collection delay), we found little difference in median blood levels for any of the metals. We 
did, however, find differences in ORs between ALS sub-groups for some metals, particularly 
for Se (Table 4). Specifically, we saw strong inverse associations of ALS with Se among 
patients with bulbar onset, lower ALSFRS-R scores, longer diagnostic delay, and longer 
collection delay whereas associations in the respective opposite categories were 
indistinguishable from null. The association of Zn with ALS did not differ by site of onset or 
by category of diagnostic delay, but it did differ by category of ALSFRS-R score or of 
collection delay. Namely, Zn was inversely associated with ALS only among patients with 
ALSFRS-R scores below the median or collection delays above the median. Associations of 
ALS with Cu and Mn did not vary by clinical features.
4. Discussion
We found associations of ALS with four trace metals: Se, Zn, Cu and Mn. Both Se and Zn 
were inversely associated with ALS. Cu was positively associated with ALS, although the 
association was weakened after adjustment for Pb. The odds of ALS exhibited an inverted 
U-shape relation with Mn levels, with the strongest positive association evident at 
intermediate Mn levels. Associations of ALS with the four metals were largely independent 
of one another. We found similar associations among a broader group of MND patients that 
also included individuals with progressive muscular atrophy.
Whole blood levels of Zn, Cu, and Mn in VALE controls were similar to levels in other 
populations (Supplemental Table 2). In contrast, Se levels in VALE controls were elevated 
compared to levels reported for European populations (Supplemental Table 2). Our blood Se 
values may be typical for the United States population; for example, levels found in 
NHANES were also elevated compared to European populations but still slightly lower than 
those in VALE controls (Jain et al., 2014; Supplemental Table 2). In general, blood Se levels 
are higher in the US, ranging from 16–40 μg/dl, than in most other parts of the world 
(Combs, 2001), but the reasons for this difference are not entirely clear. Exposure to Se 
occurs mainly through diet and only rarely through drinking water and occupation (Navarro-
Alarcon and Cabrera-Vique, 2008; Combs, 2001). Se levels in diet vary by season, 
geographical location, food processing methods, and protein content (Navarro-Alarcon and 
Cabrera-Vique, 2008; Combs, 2001), factors which may explain differences in Se levels 
between populations in the United States and elsewhere.
An important question is whether the higher Se levels in controls contributed to the inverse 
association we observed. It is unlikely that the accuracy of our assay is a critical factor. 
Although the method used may impart a positive bias to biological samples, assay 
characteristics are unlikely to vary between cases and controls and so cannot explain the 
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inverse association we found. It is however possible that differences in diet between ALS 
cases and controls may have contributed to the inverse association of Se with ALS that we 
observed.
Previous studies comparing trace metal levels in ALS patients and controls have reported 
inconsistent results, possibly because of variations in study design and small size, with 17 to 
40 patients and 9 to 40 controls in each study (Bergomi et al., 2002; Garzillo et al., 2014; 
Kapaki et al., 1997; Nagata et al., 1985; Pamphlett et al., 2001; Roos et al., 2013; 
Supplemental Table 1). These studies measured metals in various biological samples, 
including cerebrospinal fluid (CSF), whole blood, blood cells, serum or plasma, and 
toenails. The type of sample chosen for measurement does not seem to be a major 
determinant of results, although one study found that, compared to controls, ALS patients 
had high levels of Zn, Cu, and Mn in CSF but not in plasma (Roos et al., 2013). On the other 
hand, the choice of controls may have influenced results. For example, use of spouses, 
friends, or co-workers as controls (Pamphlett et al., 2001; Roos et al., 2013) may lead to 
overmatching and compromise a study’s ability to detect associations, either positive or 
inverse; such individuals often live with the cases and have similar lifestyles and occupations 
and hence similar exposures (Rothman et al., 2008). Other factors, such as the approach to 
data analysis, may also have influenced results; two of the six studies did not match controls 
to patients (Kapaki et al., 1997; Nagata et al., 1985), and only one adjusted for any 
covariates (Bergomi et al., 2002).
Previous studies of Se and ALS have reported inconsistent results. Some have suggested that 
Se exposure increases ALS risk. Veterinary observations suggested that high levels of Se are 
toxic to motor neurons in swine and cattle (reviewed in Vinceti et al., 2010), and a case 
series reported that four farmers who lived in a Se-rich environment in South Dakota 
developed ALS (Kilness and Hichberg, 1977). A small case-control study (41 patients) 
reported that drinking well water with high Se content was associated with ALS, but 
possible contaminants other than metals were not considered (Vinceti et al., 2010). One 
cross-sectional study found that ALS patients had higher blood Se levels than controls 
(Nagata et al., 1985), but three other cross-sectional studies found no difference between 
ALS patients and controls for Se levels in blood (Kapaki et al., 1997; Pamphlett et al., 2001; 
Roos et al., 2013) or CSF (Roos et al., 2013). There was a strong although imprecise inverse 
association (RR=0.3) of ALS with Se in toenails in the one study that adjusted for covariates 
(Bergomi et al., 2002). In our larger study, which also adjusted for covariates, we found a 
statistically significant inverse association of the same magnitude of ALS with Se. Further 
high quality studies will be necessary to resolve these discrepancies.
Most previous studies of Zn found little evidence for an association with ALS. Two studies 
found no difference between cases’ and controls’ Zn levels in several blood compartments 
(Nagata et al., 1985; Pamphlett et al., 2001), and another found no association with toenail 
levels (Bergomi et al., 2002). One study reported that ALS patients had higher levels of Zn 
than controls in CSF although not in plasma (Roos et al., 2013), whereas another found no 
difference in either CSF or serum levels (Kapaki et al., 1997). Our finding of an inverse 
association is inconsistent with these reports.
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Results for Cu are similarly mixed. One study found that ALS patients had lower levels of 
Cu than controls in both CSF and serum (Kapaki et al., 1997) while another reported higher 
levels in CSF and no difference in plasma (Roos et al., 2013). Other studies found no 
association of Cu with ALS in several blood compartments (Pamphlett et al., 2001) or in 
toenails (Bergomi et al., 2002). We found that Cu and Pb levels were correlated and that 
adjusting for Pb attenuated the positive association of ALS with Cu, suggesting that the 
association of ALS with Cu in the present study may reflect the association with Pb we 
previously observed (Fang et al., 2010).
Elevated Mn may contribute to the high-incidence foci of ALS in the Western Pacific 
(Bowman et al., 2011). Some studies in other locations found increased Mn levels in brain, 
spinal cord, and muscle from ALS patients (Kurlander and Patten, 1979; Mitchell et al., 
1991; Miyata et al., 1983) while others did not (Kihira et al., 1990; Pierce-Ruhland and 
Patten, 1980). Most of these studies were small, however, and the observed changes in Mn 
levels may reflect tissue degeneration. Degenerating brain tissue may undergo changes in 
number, type, or spatial distribution of neurons or glia, changes in the volume of specific 
brain regions, accumulation of aggregated proteins or other structures, or changes in the 
permeability of the blood brain barrier, all of which may change metal concentrations, 
making it difficult to infer etiological relationships (Dickson and Weller, 2011). In addition, 
methods of sample collection, storage, and processing all affect brain metal concentrations 
(Hare et al., 2012; Schrag et al., 2011), and these may differ between cases and controls. 
Among studies that measured Mn levels in blood or CSF, results were mixed. One study 
found that, compared to controls, Mn levels were elevated in serum but not CSF of ALS 
patients (Kapaki et al., 1997), while another found the reverse – an elevation among patients 
compared to controls in CSF but not plasma (Roos et al., 2013). Another study found no 
difference in Mn levels in serum of ALS patients and controls (Garzillo et al., 2014). One 
study reported an inverse association of ALS with Mn levels in blood cells (Nagata et al., 
1985), while others found null associations in several blood compartments (Pamphlett et al., 
2001) and in toenails (Bergomi et al., 2002). The explanation for our finding of an inverted 
U-shaped relationship of ALS with Mn is unclear.
Associations of metal levels with ALS progression, assessed with the ALSFRS, have also 
been evaluated in one study: ALS progression was inversely associated with Se and Zn, 
positively associated with Cu, and not related to Mn (Bergomi et al., 2002). Metals may 
have different relationships with ALS risk and progression, but it is noteworthy that our 
findings on ALS risk are consistent with these results for progression.
For the most part, associations we observed between ALS and metals did not vary by 
clinical features of the disease. One notable exception was Se, where associations with ALS 
were stronger for individuals with bulbar onset, longer diagnostic or collection delay, or a 
lower ALSFRS-R score, but not for those with the opposite characteristics. Zn showed a 
similar pattern. Thus associations with deficiencies of Se or Zn were more pronounced in 
individuals with more advanced disease, possibly suggesting that supplementation might be 
beneficial for these individuals. This could be particularly important if changes in diet 
contributed to the inverse association of Se with ALS.
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Several mechanisms might explain an association of ALS with metal levels in blood. Se and 
Zn both play a role in mitigating oxidative stress (Navarro-Alarcon and Cabrera-Vique, 
2008; Prasad, 2014; Steinbrenner and Sies, 2013). This might contribute to the inverse 
associations we observed between ALS and these metals, because oxidative stress may play 
a role in ALS etiology (Jellinger, 2013; Wijesekera and Leigh, 2009). More specifically, a 
lower risk of ALS has been found in studies where a higher intake of antioxidants in diet 
occurred (Ingre et al., 2015). Cu and Mn, on the other hand, may both increase oxidative 
stress (Martinez-Finley et al., 2013; Rivera-Manica et al., 2010), in this case potentially 
contributing to the positive associations we found between ALS and these metals. Cu and Zn 
may also play a more direct role in ALS because both are cofactors for cytosolic SOD1. 
Mutations in this enzyme, found in about 20% of familial ALS patients, lead to a toxic gain 
of function (Wijesekera and Leigh, 2009). Most polymorphisms result in misfolding of the 
SOD1 monomer, reducing its affinity for Zn and exposing the Cu binding site; this 
conformational change leads the enzyme to generate rather than detoxify reactive oxygen 
species (Rivera-Mancia et al., 2010; Trumbull and Beckman, 2009). Loss of Zn also 
contributes to dissociation of the SOD1 dimer and formation of larger aggregates, a process 
likely involved in ALS (Rivera-Mancia et al., 2010; Trumbull and Beckman, 2009). 
Decreased availability of Zn may lead the wild type SOD1 monomer to misfold, with 
consequences similar to those of the genetic polymorphisms (Rivera-Mancia et al., 2010; 
Trumbull and Beckman, 2009). Studies showing that Zn supplementation or Cu chelation 
can retard disease progression in rodent models underscore these findings and suggest that 
metal imbalance may contribute to development of sporadic ALS (Vonk and Klomp, 2008).
The primary limitation of our study is that blood was collected after diagnosis and thus 
differences in metal levels in cases compared to controls may be a consequence rather than a 
cause of ALS. It is worth noting that dietary differences between patients and controls may 
have contributed to the observed inverse association of Se with ALS. Concerns regarding 
reverse causation arise in all cross-sectional or case-control studies that measure metals in 
human tissues, but it may be a less serious problem for studies of metals in blood than for 
studies of metals in degenerating nerve or muscle. Metals in both compartments may be 
affected by disease-related changes in lifestyle or exposure opportunities, but concentrations 
in degenerating tissue will also be affected by changes related to degeneration itself 
(Dickson and Weller, 2011). A second limitation is that patients in our study tended to be 
long survivors, so that the associations we observed between metals in blood and ALS may 
reflect associations with survival as well as risk. Finally, the study subjects were primarily 
white men who had served in the United States military, potentially limiting the 
generalizability of our findings. However, our primary interest was the biological 
relationships of trace metals to ALS which would depend on the internal validity of our 
study and likely not be affected by use of a veteran population.
Our study also has major strengths, including the large sample size and use of a highly 
sensitive metal assay, which allowed us to evaluate variation at low levels. ALS diagnoses 
were made by neurologists specializing in motor neuron disease. We controlled for 
confounding by known risk factors of ALS. Because of the large study size and the 
availability of clinical information, we were uniquely able to evaluate the associations of 
ALS with metals in sub-groups of patients with different clinical features.
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5. Conclusions
We found that Se and Zn were inversely associated with ALS, particularly among patients 
with worse function, suggesting that supplementation with these metals may benefit such 
patients. In contrast, Cu was positively associated with ALS, although this relationship was 
attenuated by adjustment for Pb. While we cannot exclude reverse causation as an 
explanation for our findings, our results are consistent with those of experimental studies 
investigating the pathogenesis of ALS. Previous literature on the relationship of trace metals 
to ALS has been inconsistent. Although we cannot of course resolve all discrepancies, our 
study was considerably larger than previous ones and had a stronger study design. We 
conclude that deficiencies of Se and Zn and excess Cu may have a role in ALS etiology. This 
hypothesis should be considered in additional populations.
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Table 4
Association of blood levels of trace metals with ALS risk by clinical features.
Metal Concentration (μg/dL)
Median (Range) OR (95% CI) *¥ P-value †
Selenium (μg/dL) §
 Site of Onset
  Spinal 29.5 (15.3–66.8) 0.6 (0.3–1.3) ≤ 0.01
  Bulbar 26.3 (11.9–51.0) 0.1 (0.03–0.3)
 ALSFRS-R Score ‡
  ≤ 29 27.4 (11.9–57.0) 0.1 (0.04–0.3) ≤ 0.01
  > 29 30.7 (21.2–66.8) 1.7 (0.7–4.2)
 Diagnostic Delay (years)
  ≤ 1 29.3 (15.8–66.8) 0.7 (0.3–1.7) 0.03
  > 1 28.0 (11.9–46.5) 0.2 (0.1–0.5)
 Collection Delay (months)
  ≤ 13 30.4 (19.4–66.8) 1.3 (0.5–3.1) ≤ 0.01
  > 13 27.5 (11.9–61.0) 0.1 (0.1–0.4)
Zinc (μg/dL) §
 Site of Onset
  Spinal 602 (268–944) 0.4 (0.2–1.0) 0.71
  Bulbar 608 (353–901) 0.3 (0.1–1.2)
 ALSFRS-R Score ‡
  ≤ 29 595 (268–901) 0.2 (0.1–0.6) 0.09
  > 29 619 (325–944) 0.7 (0.2–1.9)
 Diagnostic Delay (years)
  ≤ 1 600 (268–783) 0.3 (0.1–0.7) 0.21
  > 1 612 (353–944) 0.6 (0.2–1.6)
 Collection Delay (months)
  ≤ 13 617 (268–944) 0.8 (0.3–2.2) 0.05
  > 13 579 (290–901) 0.2 (0.1–0.6)
Copper (μg/dL) §
 Site of Onset
  Spinal 88.5 (60.7–136) 2.4 (1.0–5.8) 0.21
  Bulbar 88.6 (67.3–136) 6.3 (1.5–26.2)
 ALSFRS-R Score ‡
  ≤ 29 88.9 (60.7–136) 4.2 (1.5–11.8) 0.23
  > 29 88.3 (64.5–126) 1.9 (0.7–5.5)
 Diagnostic Delay (years)
  ≤ 1 88.3 (64.5–136) 2.2 (0.8–5.8) 0.27
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Metal Concentration (μg/dL)
Median (Range) OR (95% CI) *¥ P-value †
  > 1 89.8 (60.7–136) 4.4 (1.5–12.7)
 Collection Delay (months)
  ≤ 13 88.3 (65.6–136) 3.3 (1.1–9.4) 0.78
  > 13 88.6 (60.7–136) 2.7 (1.0–7.4)
Manganese (μg/dL) ¶
 Site of Onset
  Spinal 1.0 (0.4–3.1) 0.9 (0.6–1.3) 0.92
  Bulbar 1.0 (0.5–3.3) 0.8 (0.4–1.6)
 ALSFRS-R Score ‡
  ≤ 29 1.0 (0.5–3.3) 0.9 (0.6–1.4) 0.93
  > 29 1.0 (0.5–2.9) 0.9 (0.6–1.5)
 Diagnostic Delay (years)
  ≤ 1 0.9 (0.5–1.8) 0.7 (0.4–1.1) 0.14
  > 1 1.0 (0.4–3.3) 1.1 (0.7–1.8)
 Collection Delay (months)
  ≤ 13 1.0 (0.5–3.3) 1.0 (0.6–1.7) 0.21
  > 13 1.0 (0.4–2.9) 0.7 (0.5–1.1)
*Adjusted for age, race/ethnicity.
†Comparing ORs for ALS cases with the indicated features.
§Continuous metal variables were log2-transformed. ORs correspond to a doubling of the metal level.
¶
For Mn, analysis with the categorical variable produced similar results.
‡
Three ALS cases were omitted from the analysis because ALSFRS-R scores were missing.
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